Table 3.
Different stages of T-cell differentiation and senescence-related markers.
| Markers (%) | Cell type | Controls | CM+ | CM− | Statistics (Wald) | p-Value |
|---|---|---|---|---|---|---|
| CD4+CD27+CD28+ | Early differentiated T cell | 42.0 ± 4.6a | 17.5 ± 3.9b | 19.2 ± 3.9b | 17.6 | <0.0001 |
| CD8+CD27+CD28+ | Early differentiated T cell | 27.9 ± 3.3a | 8.7 ± 1.2b | 12.0 ± 2.9b | 38.1 | <0.0001 |
| CD4+CD27−CD28+ | Intermediate-differentiated T cell | 8.74 ± 1.1a | 25.0 ± 8.8b | 25.7 ± 8.2b | 12.9 | 0.002 |
| CD8+CD27−CD28+ | Intermediate-differentiated T cell | 7.1 ± 0.9 | 6.9 ± 2.1 | 8.0 ± 1.8 | 0.2 | 0.880 |
| CD4+CD27−CD28− | Late-differentiated T cell | 13.9 ± 1.2a | 21.8 ± 2.1b | 22.9 ± 1.5b | 19.8 | <0.0001 |
| CD8+CD27−CD28− | Late-differentiated T cell | 39.4 ± 3.4 | 34.4 ± 4.6 | 42.8 ± 5.5 | 1.6 | 0.431 |
| CD3+CD56+NKG2+ | Senescent NK T cell | 0.5 ± 0.1 | 0.6 ± 0.1 | 0.7 ± 0.3 | 3.4 | 0.179 |
| CD3+CD4+KLRG1+ | Senescent T cell | 5.1 ± 0.8 | 10.7 ± 3.0 | 11.5 ± 4.0 | 3.4 | 0.183 |
| CD3+CD8+KLRG1+ | Senescent T cell | 8.7 ± 0.9 | 6.1 ± 0.9a | 9.3 ± 1.5b | 8.7 | 0.013 |
| CD4+KLRG1+NKG2+ | Senescent T cell | 5.96 ± 2.8 | 19.0 ± 4.0 | 21.0 ± 4.5 | 5.4 | 0.065 |
| CD8+KLRG1+NKG2+ | Senescent T cell | 6.0 ± 0.8a | 20.0 ± 3.9b | 24.9 ± 7.7b | 17.1 | <0.0001 |
| CD8+CD27−CD28−PD1+ | Exhausted T cell | 7.6 ± 2.5a | 78.3 ± 0.10.0b | 97.8 ± 9.7b | 55.5 | <0.0001 |
Data shown as mean percentage ± SE. Data were analyzed by Generalized Linear Modeling test (gamma or linear distribution) adjusted for age and years of education.
Statistical significant differences are highlighted in bold font.
a,bDifferences between groups (Bonferroni post hoc test).
CM+, breast cancer women with history of childhood maltreatment; CM−, breast cancer women without history of childhood maltreatment; NK, natural killer cell.